PROGNOSIS
Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism
| The first 150 words of the full text of this article appear below. |
J D Douketis
Dr J D Douketis, St Joseph's Healthcare, Hamilton, Ontario, Canada; jdouket@mcmaster.ca
STUDY QUESTIONS
In patients who have discontinued anticoagulant therapy after a first episode of venous thromboembolism (VTE), what is the risk of fatal pulmonary embolism (PE) and what is the case-fatality rate of recurrent VTE?
STUDY DESIGN
combined analysis of 2 inception cohorts followed for a mean 54 (range 1–120) months.
3 hospitals in Italy (cohort study) and 16 centres in Sweden (randomised trial).
1628 patients from the cohort study and 424 patients from the randomised trial (mean age 62 y, 53% women) who had completed
3 (mean 6) months of anticoagulant therapy (unfractionated or low-molecular-weight heparin for 5–10 d, followed by a vitamin K antagonist) after a first episode of symptomatic, objectively confirmed VTE. Patients with active cancer, permanent immobility, or high-risk thrombophilia were excluded.
age, sex, duration of initial anticoagulation, study type, initial disease presentation, and cause of
University of California, Davis Sacramento, California, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
